Compare Sibanye Stillwater Ltd (SBSW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs BIO-TECHNE Corp — how do they compare? Sibanye Stillwater Ltd trades at $10.64 (market cap $7.61B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| SBSW | TECH | |
|---|---|---|
Market Cap | $7.61B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $72.29 |
52-Week Low | $7.27 | $43.31 |
Enterprise Value | $9.26B | $11.32B |
Dividend Yield | 2.91% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sibanye Stillwater (SBSW) surged 7.6% to $10.64, showing strong momentum despite negative profitability metrics. The stock trades at attractive valuation multiples with P/E of 4.76 and P/S of 0.95, while technical indicators signal bullish momentum. Recent earnings misses contrast with analyst optimism, with 42.9% recommending Buy and a $14.25 consensus target. The company faces challenges with negative net income margins but shows improving cash flow projections for 2025.
SBSW presents a value opportunity with deep undervaluation metrics, though profitability concerns and recent earnings misses warrant caution. The bullish technical setup and analyst support suggest potential upside, but investors must weigh the company's debt reduction progress against persistent negative margins. Key catalysts include PGM price recovery and management's debt reduction targets.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
